secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001601485-23-000071
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio reports ELI-002 Phase 1 data: 87% T cell response, 86% reduced relapse risk; new preclinical data
--------------------------------------------------------------------------------

- ELI-002 Phase 1: 87% (20/23) of patients had direct ex vivo mKRAS-specific T cell responses; 100% in vitro.
- T cell response strength correlated with 86% reduced risk of relapse and death in pancreatic/colorectal cancer.
- In 4 patients assessed post-boost, 100% maintained elevated T cell responses, 75% increased further.
- ELI-007 and ELI-008 preclinical: >10-500-fold higher T cell responses vs. conventional comparators in mice.
- Data presented at SITC 2023; supports lymph node-targeting AMP platform for solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000071/0001601485-23-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148523000071/angn-20231103.htm
  HTML page:      https://secwatch.observer/filing/0001601485-23-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer